Drug intelligence / Profile preview

Wei Yan Granule No.2

Development stage: Unknown
Lead developer: Guangzhou University of Chinese Medicine
Administration: Oral

Overview

Wei Yan Granule No.2 is a Traditional Chinese Medicine (TCM) formulation developed by the Guangzhou University of Chinese Traditional Chinese Medicine. It is designed for the treatment of chronic superficial gastritis, specifically targeting patients categorized under particular TCM syndromes. The drug is part of an optimized therapeutic scheme evaluated in clinical trials to compare the efficacy of standardized TCM granules against conventional Western medicine. As a botanical-based therapy, it likely functions through multi-target anti-inflammatory and mucosal protective pathways to alleviate gastric symptoms and promote healing of the stomach lining.

Other names: Wei Yan Granule No.2

Beyond the preview

Go deeper on Wei Yan Granule No.2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wei Yan Granule No.2.

Explore the full profile